Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(4):683-690; doi:10.1093/annonc/mdj120
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/683    most recent
mdj120v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hus, I.
Right arrow Articles by Dmoszynska, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hus, I.
Right arrow Articles by Dmoszynska, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia

I. Hus1,*, M. Podhorecka1, A. Bojarska-Junak2, J. Rolinski2, M. Schmitt3, M. Sieklucka2, E. Wasik-Szczepanek1 and A. Dmoszynska1

Departments of 1 Haemato-oncology and 2 Clinical Immunology, Medical University of Lublin, Poland; 3 3rd Department of Internal Medicine, University of Ulm, Germany

* Correspondence to: Dr I. Hus, Department of Haematology, Medical University of Lublin, 20–081 Lublin, Staszica 11, Poland. Tel: +48 81 53 45 468; Fax: +48 81 53 45 605; E-mail: iwohus{at}wp.pl

Background: B-cell chronic lymphocytic leukaemia (B-CLL) is a disease with a highly variable clinical course; some patients never need treatment, while others require intensive treatment early after diagnosis. Recently, some new prognostic factors, such as IgVH mutational status, ZAP-70 and the expression of CD38 in leukaemic cells were introduced to identify attenuated versus progressive types of CLL bearing the potential to facilitate risk-adapted treatment strategies.

Patients and methods: To evaluate the clinical value of ZAP-70 and CD38 as predictors of disease progression we assessed the expression of these markers by the flow cytometry method in 156 B-CLL patients.

Results and conclusions: Both ZAP-70 and CD38 expression were shown to predict the clinical course of the disease, while ZAP-70 expression appeared to be more predictive than CD38 expression and more relevant in defining the cases of B-CLL responsive or refractory to first line chemotherapy. A simultaneous evaluation of ZAP-70 and CD38 expression allowed distinguishing the patients groups with the most favourable prognosis as well as those with the worst. Taken together we recommend assessing both ZAP-70 and CD38 protein expression for the definition of prognostic subgroups in patients with B-CLL

Key words: B-cell chronic lymphocytic leukaemia, ZAP-70, CD38


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood, September 1, 2008; 112(5): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin
Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
Physiol Rev, July 1, 2008; 88(3): 841 - 886.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Redondo-Munoz, E. Ugarte-Berzal, J. A. Garcia-Marco, M. H. del Cerro, P. E. Van den Steen, G. Opdenakker, M. J. Terol, and A. Garcia-Pardo
{alpha}4{beta}1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells
Blood, July 1, 2008; 112(1): 169 - 178.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, et al.
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells
Haematologica, March 1, 2008; 93(3): 413 - 422.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. O'Brien, J. O. Moore, T. E. Boyd, L. M. Larratt, A. Skotnicki, B. Koziner, A. A. Chanan-Khan, J. F. Seymour, R. G. Bociek, S. Pavletic, et al.
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol., March 20, 2007; 25(9): 1114 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
E. Montserrat
New Prognostic Markers in CLL
Hematology, January 1, 2006; 2006(1): 279 - 284.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.